In addition, reduced Cyp46a1 levels result in cognitive deficits, elevated production of β-amyloid peptides, and abnormal phosphorylation of tau (26) as well as in progressive loss of hippocampal neurons and an Alzheimer's disease–like phenotype (27). This evidence concerns the gene MAPT and Cognitive impairment.